Evidence map›Paper›PMID 39337337›Full record

ReviewInternational journal of molecular sciences2024

Towards Targeting Endothelial Rap1B to Overcome Vascular Immunosuppression in Cancer.

Behshid Ghadrdoost Nakhchi, Ramoji Kosuru, Magdalena Chrzanowska

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in International journal of molecular sciences, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Divergent Functions of Rap1A and Rap1B in Endothelial Biology and Disease.International journal of molecular sciences · 2025
    Review
  5. Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Behshid Ghadrdoost NakhchiVersiti Blood Research Institute, Milwaukee, WI 53226, USA.
Ramoji KosuruVersiti Blood Research Institute, Milwaukee, WI 53226, USA.ORCID 0000-0002-7394-7217
Magdalena ChrzanowskaVersiti Blood Research Institute, Milwaukee, WI 53226, USA.ORCID 0000-0003-4182-2126

Funding

Rap1 in VEGF signaling in endothelial cellsR01HL111582 · NHLBI · VERSITI WISCONSIN, INC. · PI CHRZANOWSKA, MAGDALENA · 2012 to 2019
$3.3M
NHLBI NIH HHS R01 HL111582NHLBI NIH HHS R01 HL111583
6 · The paper itself

Abstract

The vascular endothelium, a specialized monolayer of endothelial cells (ECs), is crucial for maintaining vascular homeostasis by controlling the passage of substances and cells. In the tumor microenvironment, Vascular Endothelial Growth Factor A (VEGF-A) drives tumor angiogenesis, leading to endothelial anergy and vascular immunosuppression-a state where ECs resist cytotoxic CD8

Indexed as

Neoplasmsrap GTP-Binding ProteinsAnimalsCD8-Positive T-LymphocytesEndothelial CellsEndothelium, VascularHumansImmune ToleranceImmunosuppression TherapyMiceNeovascularization, PathologicSignal TransductionTumor MicroenvironmentVascular Endothelial Growth Factor AVascular Endothelial Growth Factor Receptor-2RAP1B protein, humanrap GTP-Binding ProteinsVascular Endothelial Growth Factor AVascular Endothelial Growth Factor Receptor-2cancer therapyendothelial anergysmall GTPase Rap1tumor angiogenesisvascular immunosuppressionVEGF-A

Identifiers

PMID39337337
PMCPMC11432579

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.